Brief: Noxopharm Says FY Loss Attributable A$18.7 Million Versus Loss A$9.3 Million
25/08/2022 08:53
Aug 25 (Reuters) - Noxopharm Ltd NOX.AX :
* FY LOSS ATTRIBUTABLE A$18.7 MILLION VERSUS LOSS A$9.3
MILLION
Source text for Eikon: ID:nASX7mS5yQ
Further company coverage: NOX.AX
Recent news on Noxopharm
See all newsBrief: Noxopharm Announces SOF-SKN Manufacturing Begins To Ensure Clinical Trial Readiness
Australia's Noxopharm rises as novel cancer therapy shows potential
Brief: Noxopharm Says New Data Confirms Cancer-Fighting Potential
Brief: Noxopharm Appoints Dr Olivier Laczka As New CEO
Brief: Noxopharm Ltd Announces Resignation Of Chief Executive Officer